In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation

International Journal of Pharmaceutics

Volumn 169, Issue 1, 1998, Pages 105-113

  Talukdar, M M ^a   Van Den Mooter, G ^a   Augustijns, P ^a   Tjandra Maga, T ^a   Verbeke, N ^a   Kinget, R ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Controlled release; Hydrophilic matrices; In vivo study; Indomethacin; Sodium indomethacin; Xanthan gum

Indexed keywords

EXCIPIENT; INDOMETACIN; XANTHAN; ZOXAZOLAMINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET;

EID: 0032581116     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(98)00112-4     Document Type: Article

References (15)

1. Bacon, P., Luqmani, R.A., Barry, C., et al., 1990. A comparison of two formulations of indomethacin ('Flexin continus' tablets and 'Indocid' capsules) in the treatment of rheumatoid arthritis. Curr. Med. Res. Opin. 12, 121-127.
2. Boxenbaum, H., 1984. Pharmacokinetic determinants in the design and evaluation of sustained-release dosage forms. Pharm. Res. 1, 82-88.
3. Clarke's Isolation and Identification of Drugs' (2nd edition). 1986. Moffat. A.C. (ed.) The Pharmaceutical Press, London, pp. 681-682
4. Deasy, P.B., Law, M.F.L., 1997. Use of extrusion-spheronization to develop an improved oral dosage form of indomethacin. Int. J. Pharm. 148, 201-209.
5. McCall, T.W., Baichwal, A.R., 1994. In vitro-in vivo correlation of TimeRx metoprolol products. Proc. Int. Symp. Controlled Release Bioact. Mater. 21, 812-813.
6. Möckel, J.E., Lippold, B.C., 1993. Zero-order drug release from hydrocolloid matrices. Pharmacol. Res. 90, 1066-1070.
7. Ntawukulilyayo, J.D., Vervaet, C., Remon, J.P., Görtz, J.P., Berlo, J.A., 1996. In vitro and in vivo evaluation of xanthan gum-n-octenylsuccinate starch matrix tablet containing ibuprofen as a model drug. Int. J. Pharm. 139, 79-85.
8. Ritger, P.L., Peppas, N.A., 1987. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Release 5, 37-42.
9. Seideman, P., 1991. Lack of effect of paracetamol on the pharmacokinetics of indomethacin and paracetamol in humans. J. Clin. Pharmacol. 31, 804-807.
10. Talukdar, M.M., Kinget, R., 1995. Swelling and drug release behaviour of xanthan gum matrix tablets. Int. J. Pharm. 120, 63-72.
11. Talukdar, M.M., Michoel, A., Rombaut, P., Kinget, R., 1996a. Comparative study on xanthan gum and hydroxypropylmethyl cellulose as matrices for controlled-release drug delivery: I. compaction and in vitro drug release behaviour. Int. J. Pharm. 129, 233-241.
12. Talukdar, M.M., Vinckier, I., Moldenaers, P., Kinget, R., 1996b. Rheological characterization of xanthan gum and hydroxypropylmethyl cellulose with respect to controlled-release drug delivery. J. Pharm. Sci. 85, 537-540.
13. Talukdar, M.M., Kinget, R., 1997a. Comparative study on xanthan gum and hydroxypropyl methyl cellulose as matrices for controlled-release drug delivery: II. drug diffusion in hydrated matrices. Int. J. Pharm. 151, 99-107.
14. Talukdar, M.M., Rombaut, P., Kinget, R., 1997b. On the release mechanism of indomethacin from xanthan gum matrix tablets, Pharm. Dev. Technol. In press.
15. Vial-Bernasconi, A.C., Buri, P., Doelker, E., Beyssac, E., Duchaix, G., Aiiache, J.M., 1995. In vivo evaluation of an indomethacin monolithic, extended zero-order release hard-gelatin capsule formulation based on saturated polyglycolysed glycerides. Pharm. Acta. Helv. 70, 307-313.